Method to treat age-related macular degeneration

Abstract

Age-related macular degeneration (AMD) results in the formation of new blood vessels in the eye. The walls of these vessels leak fluid, which causes scarring in the surrounding tissue and results in reduced vision or loss of vision. Photodynamic therapy (PDT) alone has been used to treat AMD, but many retreatments are needed, which cause further damage to the already diseased area. Laser treatment to coagulate the fluid actually causes additional new vessels to form. However, the inventive method of treating patients with both PDT and scatter threshold laser coagulation therapy surprisingly either improved vision, or prevented further loss of vision. Moreover, the combined treatment eliminated the need for retreatment, and did not generate new vessel growth. Threshold laser coagulation and PDT may be administered within the same treatment session or either may be administered first and the other may be administered within ninety days.

Description

[0001] This application is a Divisional of U.S. application Ser. No. 10 / 008,296, filed Nov. 13, 2001, and a Divisional of U.S. application Ser. No. 10 / 107,761, filed Mar. 27, 2002, which is a Continuation-In-Part of U.S. application Ser. No. 10 / 008,296, filed Nov. 13, 2001, the disclosures of which are hereby incorporated herein by reference in their entirety.FIELD OF THE INVENTION [0002] The invention is directed generally to an ophthalmological process, and more specifically to a process to improve, maintain, or reduce loss of visual acuity in a patient having or at risk for developing macular degeneration. BACKGROUND OF THE INVENTION [0003] In the mammalian eye, macular degeneration (also called age related macular degeneration, AMD) is a pathological condition that is the most common cause of legal blindness among individuals over the age of 60, with an incidence ranging from 11% to 18.5% in individuals over the age of 85. In the United States, AMD affects roughly 3.6 million in...

AI Technical Summary

Benefits of technology

[0016] The invention is directed to a method to prevent, alleviate, or delay the onset of age-related macular degeneration AMD in a patient by administering photodynamic therapy (PDT) simultaneously or concomitantly with scatter threshold laser coagulation therapy. The invention is also directed to a method to prevent the progression of AMD, and to reduce further loss of vision in a patient having AMD, by administering PDT simultaneously or concomitantly with scatter threshold laser coagulation therapy. Surprisingly and beneficially, with the combined therapies, there is no need for retreatment of patients, as is required when PDT is separately administered, and there are no laser-induced neovascularizations, as occur in about 30% of patents to whom laser coagulation therapy is separately administered. Another benefit of the invention is that visual acuity is either maintained or is improved, without further loss of vision. The inventive therapy may be administered in any sequence, that is, scatter threshold laser coagulation therapy may be administered before or after PDT, or simultaneously with PDT. The invention can be used for both exudative and atrophic types of AMD.

[0018] The invention is also directed to a method to improve visual acuity, and / or prevent further loss of vision in a patient already diagnosed with AMD, using the method described above.

[0019] The invention is further directed to a method to reduce the recurrence of new vessels in an eye of a patient having undergone PDT to treat AMD by further treating the patient with scatter threshold laser coagulation therapy concomitantly with the PDT in progress. The scatter threshold laser coagulation therapy may be administered within a few minutes of PDT, with a few hours of PDT, within 24 hours of PDT, or even ninety days after PDT. Alternatively, the scatter threshold laser coagulation therapy may have been administered, and thereafter the patient's standard PDT may be administered within a few minutes, within a few hours, within 24 hours, or up to ninety days after scatter threshold laser coagulation therapy.

[0020] The invention is also directed to a method to reduce the recurrence of new vessels in an eye of a patient having undergone laser coagulation therapy for AMD by further treating the patient with PDT concomitantly with laser coagulation therapy in progress, as described above. Alternatively, PDT may be administered first, and then the patient's standard laser coagulation laser therapy may be administered.

[0021] The invention is additionally directed to a method to minimize photosensitivity of a patient undergoing or having undergone PDT by administering the photosensitive agent to vessels of the patient and activating the agent with a low energy light, then treating the patient with plasmaphoresis to reduce the concentration of the agent in the patient's blood, or treating the patient with a compound to decrease the activity of the photosensitive agent. In patients with AMD, plasmaphoresis is also beneficial in removing lipid components of the blood that may aggravate the disease, such as cholesterol and low density lipoproteins.

Problems solved by technology

The photoactivated agent produces activated oxygen species, such as hydroxyl radicals and other radicals, that damage the new vessels, and may occlude the vessels.

This results in coagulation of the fluid within and surrounding the new vessels.

Images